📋 Tender Overview
The DAK-Gesundheit intends to conclude non-exclusive discount agreements for pharmaceuticals under the relevant legal provisions. This involves a formal procurement process for the active ingredient Abiraterone (excluding the strength of 500 mg), ATC L02BX03, with interested pharmaceutical companies. The contracts will commence on October 1, 2026, and end on December 31, 2027, with an option for a 12-month extension. The process allows all pharmaceutical companies to participate without discrimination. Abiraterone